

OMB No.: 0915-0285. Expiration Date: 1/31/2020

DEPARTMENT OF HEALTH AND HUMAN SERVICES	FOR HRSA	USE ONLY	
Health Resources and Services Administration	Grant Number	Application Tracking	
SAMPLE CLINICAL PERFORMANCE MEASURE		Number	
All applicants are required to complete all fields unless otherwise stated. Example responses are provided for one Clinical Performance Measure - Diabetes	XYZ Health Center	000000	
Focus Area: Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) This field contains the content area description for each required performance measure. Applicants will specify focus areas when adding performance measures in the Additional Performance Measures section. Performance Measure This field defines each performance measure and is editable			
for performance measures in the Additional Performance Measures section. Edits must be explained in the Comments field.	who had hemoglobin A1c > 9.0% during the measurement period.		
Target Goal Description <i>This field provides a description of the target goal.</i>	By December 31, 2020, decrease the percentage of adult patients with type 1 or 2 diabetes whose most recent HbA1c is greater than 9% from 65% to 55%.		
Numerator Description In the Clinical Performance Measures, the numerator is the number of patients that meet the criteria identified by the measure (e.g., patients in a specified age range that received a specified service). This field can be edited for any previously self-defined performance measure. All edits require justification in the Comments field.	Patients whose most recent HbA1c level performed during the measurement period is > 9.0% or who had no test conducted during the measurement period.		
Denominator Description In the Clinical Performance Measures, the denominator is all patients to whom the measure applies (e.g., patients in a specified age range, regardless of whether they received a specified service). This field can be edited for any previously self-defined performance measure. All edits require justification in the Comments field.	Patients 18-75 years of age with Type 1 or Type 2 diabetes with a medical visit during the measurement period, excluding patients with a diagnosis of secondary diabetes due to another condition and patients who were in hospice care during the measurement period		
Baseline Data Competing continuation applicants: These fields will be blank and editable for the revised Clinical Performance Measure(s), since no UDS data is available. Otherwise, data pre-populate from the UDS report and are not editable. For pre-populated, non-editable data, to report more current data, include information in the Comments field. New and competing supplement applicants: These fields will	Baseline Year: 2017 Measure Type: Percentage Numerator: 2600 Denominator: 4000		
be blank and editable. For previously-self defined Additional Performance Measures, pre-populated information can be edited. Justification is required in the Comments field.	Calculated Baseline: 65%		

DEPARTMENT OF HEALTH AND HUMAN SERVICES	FOR HRSA	USE ONLY
Health Resources and Services Administration	Grant Number	Application Tracking
SAMPLE CLINICAL PERFORMANCE MEASURE		Number
All applicants are required to complete all fields unless otherwise stated. Example responses are provided for one Clinical Performance Measure - Diabetes	XYZ Health Center	000000
Progress Field Competing continuation applicants MUST use this field to provide information regarding progress since the application that initiated the budget period. State If progress cannot be reported due to the required measure being revised. This field is not applicable for new and competing supplement applicants.	Percentage of adult (18 to 75 years old) diabetic patients whose HbA1c levels are greater than 9% has decreased to 65%. This is a decrease of 6% (from 71% since initiation of the current project period in 2016.	
Projected Data (by December 31, 2020)	55%	
This field provides the goal to be met by December 31, 2020. Data Source & Methodology Applicants are required to identify a data source and discuss the restleadeler used to collect and enalging data	Data Source: [X] EHR [_] Chart Audit [_] Other (If Other, please specify) :	
the methodology used to collect and analyze data. For Clinical Performance Measures, applicants must select the data source—EHR, Chart Audit, or Other (please specify)— before describing the methodology.	Data Source and Methodology Description: Audit of all applicable patient records utilizing EHR system installed in 2010. (Data from 2017 UDS report – data run occurred (1/7/2018).	
 Key Factor and Major Planned Action #1 The Key Factor Type subfield requires applicants to select Contributing and/or Restricting factor categories. Applicants must specify at least one key factor of each type. The Key Factor Description subfield provides a description of the factors predicted to contribute to and/or restrict progress toward stated goals. The Major Planned Action Description subfield provides a description of the major actions planned for addressing key factors. Applicants must use this subfield to provide planned overarching action steps and strategies for achieving each performance measure. 	 Key Factor Type: [X] Contributing [_] Restricting Key Factor Description: XYZ offers a variety of pharmaceutical assistance programs, including the provision of free, discounted, or generic medications as well as medications through its 340B Federal Drug Pricing arrangement. At least 70% of diabetic patients are on a total of 3 to 8 medications because of co-morbidities and complications. The pharmaceutical assistance programs improve compliance by helping relieve the financial burden of multiple prescribed medications. Major Planned Action Description: Increase education and outreach efforts to diabetic patients on using the pharmaceutical assistance programs to improve medication adherence and ultimately improve HbA1c. 	
Key Factor and Major Planned Action #2	 Key Factor Type: [_] Contributing [X] Restricting Key Factor Description: Integrating Diabetes Collaborative activities into the current work flow remains challenging. The agency-wide team would like to meet more frequently, but providers have little allocated administrative time and full clinical schedules. Any additional system stress negatively affects patient care management. Major Planned Action Description: Implement daily huddles with the care team that 	
Comments (optional) Provide justifications required from changes made to other	includes time to share qualit discuss interventions to imp XYZ is participating in a stat	y dashboard updates and rove care delivery.
form fields as well as any additional information desired.	outcomes for patients with d	

DEPARTMENT OF HEALTH AND HUMAN SERVICES	FOR HRSA USE ONLY	
Health Resources and Services Administration	Grant Number	Application Tracking Number
SAMPLE CLINICAL PERFORMANCE MEASURE		Number
All applicants are required to complete all fields unless otherwise stated. Example responses are provided for one Clinical Performance Measure - Diabetes	XYZ Health Center	000000
Competing Continuation Applicants: May provide baseline data		1
updates, as applicable, and/or other comments as desired.		

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this project is 0915-0285. Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 14-N39, Rockville, Maryland, 20857.